Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.
1. A method for inhibiting endothelial cell motility, vessel formation and inducing vessel dissociation in a mammal diagnosed as having a chronic wound, comprising administering to the mammal an effective amount of a compound comprising a peptide that is at least 95% identical to the peptide of SEQ ID NO: 1; wherein said peptide binds with and activates chemokine receptor CXCR3 and wherein said activation of the chemokine receptor CXCR3 inhibits endothelial cell motility and vessel formation and induces vessel dissociation; and wherein the compound is applied to said chronic wound in the form of a topical formulation having said compound in a topical carrier; and wherein said topical formulation comprises two or more compounds that are ligands of chemokine receptor CXCR3.
2. The method according to claim 1 , wherein said peptide is SEQ ID NO: 1.
3. A method for mediating regression of vascular vessels to inhibit angiogenisis in a mammal diagnosed as having a chronic wound, said method comprising administering to a mammal an effective amount of a compound comprising a peptide that is at least 95% identical to the peptide of SEQ ID NO:1; and wherein said peptide binds with and activates chemokine receptor CXCR3 and wherein said activation with the chemokine receptor CXCR3 mediates regression of vascular vessels to inhibit angiogenesis; and wherein the compound is applied to said chronic wound in the form of a topical formulation having said compound in a topical carrier; and wherein said topical formulation comprises two or more compounds that are ligands of chemokine receptor CXCR3.
4. The method according to claim 3 , wherein said peptide is SEQ ID NO: 1.